Trial Profile

CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YTS 101 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Mar 2022 Status changed from suspended to completed.
29 Jan 2022 Planned End Date changed from 10 Nov 2021 to 10 Dec 2022.
29 Jan 2022 Planned primary completion date changed from 10 Aug 2021 to 10 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com